Directly observed therapy and treatment completion for tuberculosis in the United States: Is universal supervised therapy necessary?

American Journal of Public Health

Volumn 88, Issue 7, 1998, Pages 1052-1058

  Bayer, Ronald ^a   Stayton, Catherine ^a   Desvarieux, Moïse ^c   Healton, Cheryl ^a   Landesman, Sheldon ^b   Tsai, Wei Yann ^c  

^a Department of Medicine   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c Columbia School of Public Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES;

EID: 0031820023     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.88.7.1052     Document Type: Article

References (27)

1. Addington W. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest. 1979;76(suppl):6.
2. Tuberculosis Chemotherapy Centre, Madras. A current comparison of home and sanitorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1959;21: 51-144.
3. Fox W. The problem of self-administration of drugs, with particular references to pulmonary tuberculosis. Tubercle. 1958;39:269-274.
4. Fox W. Self-administration of medicaments: a review of published work and a study of problems. In: Proceedings of the XVI International Conference on Tuberculosis. 1962:307-331.
5. Fox W. The chemotherapy and epidemiology of tuberculosis: some findings of general applicability from the Tuberculosis Chemotherapy Centre, Madras. Lancet. 1962;473-478.
6. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;354:1545-1548.
7. Centers for Disease Control and Prevention. Tuberculosis morbidity-United States, 1992. MMWR Morb Mortal Wkly Rep. 1993; 42:696-697, 703-704.
8. Centers for Disease Control and Prevention. Nosocomial transmission of multi-drug resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. JAMA. 1991;226:1483-1485.
9. American Thoracic Society, Centers for Disease Control and Prevention, American Academy of Pediatrics, Infectious Disease Society of America. Control of tuberculosis in the United States. Am Rev Respir Dis. 1992; 146:1623-1633.
10. Advisory Council for the Elimination of Tuberculosis. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1993;42(RR-7).
11. Fiscal Year 1994 Application Guidance for Non-Completing Continuation Applications for Tuberculosis (TB) Elimination Cooperative Agreements. Atlanta, Ga: Centers for Disease Control and Prevention; 1994.
12. Fiscal Year 1995 Application Guidance for Non-Completing Continuation Applications for Tuberculosis (TB) Elimination Cooperative Agreements. Atlanta, Ga: Centers for Disease Control and Prevention; 1995.
13. Voelker R. 'Shoe leather' therapy is gaining on TB. JAMA. 1996;275:743-744.
14. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse of tuberculosis. N Engl J Med. 1994;330:1179-1184.
15. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City: turning the tide. N Engl J Med. 1995;333: 229-233.
16. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA. 1996;276: 1223-1228.
17. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-951.
18. Cowell A. U.N. agency is optimistic on treatment to fight TB. New York Times. March 20, 1997: A1.
19. Bloch AB, Onorato IM, Ihle WW, Hadler JL, Hayden CH, Snider DE. The need for epidemic intelligence. Public Health Rep. 1996;3:26-33.
20. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med. 1993; 328:576-578.
21. Bayer R, Dubler NN, Landesman S. The dual epidemics of tuberculosis and AIDS: ethical and policy issues in screening and treatment. Am J Public Health. 1993;83:649-654.
22. Annas G. Control of tuberculosis: the law and the public health. N Engl J Med. 1993;328: 585-588.
23. Hansell DA. The TB and HIV epidemics: history learned and unlearned. J Law Med Ethics. 1993;21:376-381.
24. Jacobs SL. Legal advocacy in a time of plague. J Law Med Ethics. 1993;21:382-389.
25. Goldstein A. D.C. shows jump in TB cases; study blasts city's efforts to track, fight disease. Washington Post. August 2, 1996:C1.
26. Bloch AB, Simone PM, Kelly GD, Dansbury KG, McCray E, Castro KG. Comparison of two methods for calculating completion of tuberculosis therapy in the US, 1993. Paper presented at: American Thoracic Society International Conference; May 1997: San Francisco, Calif.
27. Nardell EA. Beyond four drugs: public health policy and the treatment of the individual patient with tuberculosis. Am Rev Respir Dis. 1993;148:2-5.